

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: **ISPH-0766**
Inventors: **Gaarde et al.**
Serial No.: **Not Yet Assigned**
Filing Date: **Herewith**
Examiner: **Not Yet Assigned**
Group Art Unit: **Not Yet Assigned**
Title: **Antisense Modulation of PPAR-delta
Expression**

"Express Mail" Label No. **EL976562685US**
Date of Deposit **September 5, 2003**

I hereby certify that this paper is being deposited
with the United States Postal Service "Express Mail
Post Office to Addressee" service under 37 CFR 1.10
on the date indicated above and is addressed to the
Commissioner for Patents, Mail Stop Sequence, P. O.
Box 1450, Alexandria, VA 22313-1450.

By *Jane Massey Licata*
Typed Name: **Jane Massey Licata, Reg. No. 32,257**

Commissioner for Patents
Mail Stop Sequence
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

- (XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.
- () In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:
- () Certification in Accordance with §1.97(e) is set forth below; or
- () The fee of \$180.00 as set forth in §1.17(p) is attached.
- () In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I)(1).
- () Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

(XX) In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. 10/160,807, filed May 31, 2002 for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

() The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(XX) All listed references are in the English language.

Respectfully submitted,



Jane Massey Licata
Registration No. 32,257

Date: September 5, 2003

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515

Form PTO-1449 Modified		Docket No. ISPH-0766	Serial No. Not yet assigned
List of Patents and Publications Cited by Application (Use several sheets if necessary)		Applicant William Gaarde et al.	
		Filing Date Herewith	Group
U.S. Department of Commerce Patent and Trademark Office			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AA	Amri et al., Cloning of a protein that mediates transcriptional effects of fatty acids in preadipocytes. Homology to peroxisome proliferator-activated receptors, <i>J. Biol. Chem.</i> , 1995 , 270:2367-2371	
	AB	Basu-Modak et al., Peroxisome proliferator-activated receptor beta regulates acyl-CoA synthetase 2 in reaggregated rat brain cell cultures, <i>J. Biol. Chem.</i> , 1999 , 274:35881-35888	
	AC	Berger et al., Novel Peroxisome Proliferator-activated Receptor (PPAR) gamma and PPARDelta Ligands Produce Distinct Biological Effects, <i>The Journal of Biological Chemistry</i> , 1999 , 274:6718-6725	
	AD	Gupta et al., Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer, <i>Proc. Natl. Acad. Sci. U. S. A.</i> , 2000 , 97:13275-13280	
	AE	He et al., PPARDelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs, <i>Cell</i> , 1999 , 99:335-345	
	AF	Jow et al., The human peroxisome proliferator-activated receptor (PPAR) subtype NUC1 represses the activation of hPPAR alpha and thyroid hormone receptors, <i>J. Biol. Chem.</i> , 1995 , 270:3836-3840	
	AG	Lim et al., PPARDelta Functions as a Prostacyclin Receptor in Blastocyst Implantation, <i>Trends Endocrinol. Metab.</i> , 2000 , 11:137-142	
	AH	Lim et al., Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARDelta, <i>Genes Dev.</i> , 1999 , 13:1561-1574	
	AI	Loviscach et al., Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: relation to insulin action, <i>Diabetologia</i> , 2000 , 43:304-311	
EXAMINER		DATE CONSIDERED	

DOCKET NO.: ISPH-0766

Form PTO-1449 Modified		Docket No. ISPH-0766	Serial No. Not yet assigned
List of Patents and Publications Cited by Application (Use several sheets if necessary)		Applicant William Gaarde et al.	
		Filing Date Herewith	Group
U.S. Department of Commerce Patent and Trademark Office			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AJ	Mano et al., Cloning and function of rabbit peroxisome proliferator-activated receptor delta/beta in mature osteoclasts, J. Biol. Chem., 2000, 275:8126-8132	
	AK	Schmidt et al., Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids, Mol. Endocrinol., 1992, 6:1634-1641	
	AL	Yoshikawa et al., Assignment of the human nuclear hormone receptor, NUC1 (PPARD), to chromosome 6p21.1-p21.2, Genomics, 1996, 35:637-638	
EXAMINER		DATE CONSIDERED	

DOCKET NO.: ISPH-0766

Form PTO-1449 Modified List of Patents and Publications Cited by Application (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. ISPH-0766	Serial No. Not yet assigned
Applicant William Gaarde et al.		Filing Date Herewith	
Group			

U.S. PATENT DOCUMENTS						
Examiner's Initial		Document No.	Date	Name	Class	Subclass
	AA	5,861,274	01/19/1999	Evans et al.	435	69.1
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					
	AL					
	AM					
	AN					

FOREIGN PATENT DOCUMENTS						
Examiner's Initial		Document No.	Date	Country	Translation YES NO	
	AO	WO 96/01317	01/18/1996	PCT	X	
	AP					
	AQ					
	AR					
	AS					
	AT					
	AU					
	AV					
	AW					
	AX					

EXAMINER	DATE CONSIDERED
----------	-----------------